Our top pick for
Building a portfolio
Equillium, Inc is a biotechnology business based in the US. Equillium shares (EQ) are listed on the NASDAQ and all prices are listed in US Dollars. Equillium employs 26 staff and has a market cap (total outstanding shares value) of USD$115.2 million.
|Latest market close||USD$4.59|
|52-week range||USD$2.2 - USD$19.22|
|50-day moving average||USD$4.7342|
|200-day moving average||USD$6.2797|
|Wall St. target price||USD$16.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.413|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-15)||-11.73%|
|1 month (2020-12-23)||-2.34%|
|3 months (2020-10-23)||-21.40%|
|6 months (2020-07-22)||-65.70%|
|1 year (2020-01-22)||10.87%|
|2 years (2019-01-22)||-60.19%|
|3 years (2018-01-19)||N/A|
|5 years (2016-01-19)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-22.68%|
|Return on equity TTM||-44.79%|
|Market capitalisation||USD$115.2 million|
TTM: trailing 12 months
There are currently 480,722 Equillium shares held short by investors – that's known as Equillium's "short interest". This figure is 29.8% down from 684,913 last month.
There are a few different ways that this level of interest in shorting Equillium shares can be evaluated.
Equillium's "short interest ratio" (SIR) is the quantity of Equillium shares currently shorted divided by the average quantity of Equillium shares traded daily (recently around 763050.79365079). Equillium's SIR currently stands at 0.63. In other words for every 100,000 Equillium shares traded daily on the market, roughly 630 shares are currently held short.
However Equillium's short interest can also be evaluated against the total number of Equillium shares, or, against the total number of tradable Equillium shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Equillium's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Equillium shares in existence, roughly 20 shares are currently held short) or 0.0335% of the tradable shares (for every 100,000 tradable Equillium shares, roughly 34 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Equillium.
Find out more about how you can short Equillium stock.
We're not expecting Equillium to pay a dividend over the next 12 months.
Over the last 12 months, Equillium's shares have ranged in value from as little as $2.2 up to $19.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Equillium's is 1.731. This would suggest that Equillium's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Equillium, Inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.